Expression of antisense to integrin subunit β3 inhibits microvascular endothelial cell capillary tube formation in fibrin

Susan M. Dallabrida, Michelle A. De Sousa, David Farrell

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

α(v)β3 antagonists are potent angiogenesis inhibitors, and several different classes of inhibitors have been developed, including monoclonal antibodies, synthetic peptides, and small organic molecules. However, each class of inhibitor works by the same principal, by blocking the binding of ligands to α(v)β3. In an effort to develop an α(v)β3 inhibitor that down-regulates the actual level of α(v)β3, we developed an antisense strategy to inhibit α(v)β3 expression in vitro. β3 antisense expressed in endothelial cells specifically down-regulated α(v)β3 and inhibited capillary tube formation, with the extent of down-regulation correlating with the extent of tube formation inhibition. This inhibition was matrix-specific, since tube formation was not inhibited in Matrigel. These findings support the notion that α(v)β3 is required for an essential step of angiogenesis in fibrin, namely capillary tube formation. These results suggest that pseudogenetic inhibition of β3 integrins using antisense techniques may ultimately provide a therapeutic means to inhibit angiogenesis in vivo.

Original languageEnglish (US)
Pages (from-to)32281-32288
Number of pages8
JournalJournal of Biological Chemistry
Volume275
Issue number41
StatePublished - Oct 13 2000

Fingerprint

Capillary tubes
Endothelial cells
Fibrin
Integrins
Down-Regulation
Endothelial Cells
Angiogenesis Inhibitors
Monoclonal Antibodies
Ligands
Peptides
Molecules
Therapeutics
matrigel
In Vitro Techniques

ASJC Scopus subject areas

  • Biochemistry

Cite this

Expression of antisense to integrin subunit β3 inhibits microvascular endothelial cell capillary tube formation in fibrin. / Dallabrida, Susan M.; De Sousa, Michelle A.; Farrell, David.

In: Journal of Biological Chemistry, Vol. 275, No. 41, 13.10.2000, p. 32281-32288.

Research output: Contribution to journalArticle

@article{a5ee5959bad34a9b8e2794df9eb47b86,
title = "Expression of antisense to integrin subunit β3 inhibits microvascular endothelial cell capillary tube formation in fibrin",
abstract = "α(v)β3 antagonists are potent angiogenesis inhibitors, and several different classes of inhibitors have been developed, including monoclonal antibodies, synthetic peptides, and small organic molecules. However, each class of inhibitor works by the same principal, by blocking the binding of ligands to α(v)β3. In an effort to develop an α(v)β3 inhibitor that down-regulates the actual level of α(v)β3, we developed an antisense strategy to inhibit α(v)β3 expression in vitro. β3 antisense expressed in endothelial cells specifically down-regulated α(v)β3 and inhibited capillary tube formation, with the extent of down-regulation correlating with the extent of tube formation inhibition. This inhibition was matrix-specific, since tube formation was not inhibited in Matrigel. These findings support the notion that α(v)β3 is required for an essential step of angiogenesis in fibrin, namely capillary tube formation. These results suggest that pseudogenetic inhibition of β3 integrins using antisense techniques may ultimately provide a therapeutic means to inhibit angiogenesis in vivo.",
author = "Dallabrida, {Susan M.} and {De Sousa}, {Michelle A.} and David Farrell",
year = "2000",
month = "10",
day = "13",
language = "English (US)",
volume = "275",
pages = "32281--32288",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "41",

}

TY - JOUR

T1 - Expression of antisense to integrin subunit β3 inhibits microvascular endothelial cell capillary tube formation in fibrin

AU - Dallabrida, Susan M.

AU - De Sousa, Michelle A.

AU - Farrell, David

PY - 2000/10/13

Y1 - 2000/10/13

N2 - α(v)β3 antagonists are potent angiogenesis inhibitors, and several different classes of inhibitors have been developed, including monoclonal antibodies, synthetic peptides, and small organic molecules. However, each class of inhibitor works by the same principal, by blocking the binding of ligands to α(v)β3. In an effort to develop an α(v)β3 inhibitor that down-regulates the actual level of α(v)β3, we developed an antisense strategy to inhibit α(v)β3 expression in vitro. β3 antisense expressed in endothelial cells specifically down-regulated α(v)β3 and inhibited capillary tube formation, with the extent of down-regulation correlating with the extent of tube formation inhibition. This inhibition was matrix-specific, since tube formation was not inhibited in Matrigel. These findings support the notion that α(v)β3 is required for an essential step of angiogenesis in fibrin, namely capillary tube formation. These results suggest that pseudogenetic inhibition of β3 integrins using antisense techniques may ultimately provide a therapeutic means to inhibit angiogenesis in vivo.

AB - α(v)β3 antagonists are potent angiogenesis inhibitors, and several different classes of inhibitors have been developed, including monoclonal antibodies, synthetic peptides, and small organic molecules. However, each class of inhibitor works by the same principal, by blocking the binding of ligands to α(v)β3. In an effort to develop an α(v)β3 inhibitor that down-regulates the actual level of α(v)β3, we developed an antisense strategy to inhibit α(v)β3 expression in vitro. β3 antisense expressed in endothelial cells specifically down-regulated α(v)β3 and inhibited capillary tube formation, with the extent of down-regulation correlating with the extent of tube formation inhibition. This inhibition was matrix-specific, since tube formation was not inhibited in Matrigel. These findings support the notion that α(v)β3 is required for an essential step of angiogenesis in fibrin, namely capillary tube formation. These results suggest that pseudogenetic inhibition of β3 integrins using antisense techniques may ultimately provide a therapeutic means to inhibit angiogenesis in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0034644684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034644684&partnerID=8YFLogxK

M3 - Article

VL - 275

SP - 32281

EP - 32288

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 41

ER -